Company
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1094 stories · page 9 of 11
“Disposing the remaining rights to the medicines allows both companies to benefit from greater efficiencies as AstraZeneca continues to focus our resources on our three main therapy areas”
Shire remains the "standout stock" as it has an "extremely compelling valuation”, according to JP Morgan
The new chief executive joins Teva - the world's biggest seller of generics medicines - from Denmark's H. Lundbeck A/S, where he has been president and CEO since May 2015
Analysts see the results of phase III trials for Imfinzi and Tagrisso as a positive development for AstraZeneca but have raised concerns about other areas of the business
AstraZeneca is making progress in trials of its lung cancer treatments
The blue chip index closed out almost 36 points higher at 7,413
The FTSE 100 retreated as investors worry about Hurricane Irma, while mixed economic statistics raised fresh concerns over the UK economy.
Celegene said the FDA's decision was due to risks seen in other trials for another checkpoint inhibitor, Merck & Co.'s anti-PD-1 antibody pembrolizumab, in combination with immunomodulatory agents
The Natixis analysts said: “We expect successful results for MYSTIC, which prompts our target of 5,738p, up from 5,000p previously, but still giving over 25% upside potential”
FTSE 100 closed down 18.79 at 7,354, while the FTSE 250 lost over 74 points at 19,652.
Faslodex can now be deployed as a single therapy following regulatory sign off
The collaboration will help Astra develop further therapeutic approaches for patients
Lynparza was initially approved to be given to women with advanced ovarian cancer who had stopped responding to three rounds of chemotherapy
The FTSE 100 finished 108 points lower at 7,390, about 13 points above its intra-day low
It has been granted a priority review by the US Food & Drug Administration for acalabrutinib, which has been developed to treat a rare form of non-Hodgkin’s lymphoma
AstraZeneca is making progress on its lung cancer drug Imfinzi but suffered a set back on its Mystic treatment
AstraZeneca has maintained that its Mystic lung cancer treatment could be positive on improving overall survival rates after a failed trial
Merck & Co is yet to determine the full impact of the ‘Petya’ cyber attack in June that disrupted operations
Despite the beating meted out to IMPs and BATs, the Footsie rallied in the last half hour to trim its heavy losses
Liberum’s price target is £20 a share, which is £4.32 below the current price
There was a lot of hope and expectation factored into the share price ahead of the findings with AZ up 20% from January
It had been hoped that the combination of two of its lead immuno-oncology compounds, Imfinzi and tremelimumab, would lead the drugmaker into a new era
Archive
It's been a busy day here in London; 15% of FTSE 100-listed companies have had some sort of meaningful news out...
Archive
Lloyds Banking Group and Royal Dutch Shell are among a slew of companies reporting earnings on Thursday
Archive
Week ahead: Lloyds, Barclays, AstraZeneca, GlaxoSmithKline, Sky, Reckitt Benckiser
London stocks were on the front foot this morning, but they quickly retreated this afternoon...
Archive
Of course if you’ve already done so, this article probably doesn’t apply to you…
The Footsie closed down on the day but up on the week
Financial news website Calcalist has reported that Soriot is close to being unveiled as Teva’s new boss
Investments and investor services
Footsie was becalmed throughout the day, leaving the mid-cap FTSE 250 to claim the limelight
Citi has gone to ‘neutral’ from ‘buy’ on GSK shares, which it reckons are worth £17 each
The Republicans are looking to repeal Obamacare as well as trying to ease regulatory pressures in the industry
The UK blue chip index closed down around 15 points at 7,424
Rubraca is one of a new type of cancer treatment called PARP-inhibitors
Archive
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
The broker has been bullish on the sector since November’s US elections, in which time the sector has advanced 20%, or 12% in relative terms.
The blue chip FTSE 100 index closed 28 points down at 7,449
The Swiss firm will pay AstraZeneca US$200mln upon completion of the deal, and AstraZeneca will also receive up to an additional $102mln in future milestone payments
Investments and investor services
FTSE 100 closed below the 7,500 level as traders sit and wait it out..
There were also promising readouts from a prostate cancer trial and an early-stage ovarian cancer study
The results bode well for Astra, which is looking to build a successful oncology franchise
Archive
Election to dominate as polls suggest a turbulent week ahead while cancer forum will put spotlight on pharma
“It would be easy to downgrade Astra here,” said analyst Roger Franklin.
The company is pleased with the progress made with the LOXL2 programme and clearly is not giving up on its IFN-beta candidate
That’s according to Deutsche Bank, but analysts at HSBC aren’t quite so sure
It's a case of "in for a Penney, in for a pounding" today
Merck seems to be ahead in the race to develop the number one lung cancer treatment, but for how long?
It bodes well for the upcoming readout of the MYSTIC trial which is what investors and the markets are really waiting for
At the close, the UK blue chip index was up 0.7%, or 48.8 points at 7,435.4, not far below its all-time record of 7,447.0
Investments and investor services
The Footsie was back in black - but only just - thanks to precious metals miners
The company estimates Imfinzi could eventually become a blockbuster product with peak sales of US$6.5bn.
Copycat competition for big sellers such as cholesterol-buster Crestor ate into first quarter revenues, which fell by 12% to US$5.54bn in the first-quarter.
Herencia Resources is a high riser among London's small caps today as it prepares a drill plan to enhance its copper projects
The company, which developed and out-licensed AZD9412, believes the interferon beta candidate has potential.
Circassia booked restructuring costs and impairments of £80.0mln in 2016 leading it to report a pretax loss of £144.9mln, up from a £62.8mln loss in 2015
Archive
Week ahead: Huge for blue chip announcements with four high street banks, the UK’s two pharma giants, mining titans Anglo and BHP and restaurant to coffee chain Whitbread just a few of those updating.
Archive
At the end of January, John Harrington tweaked the famous investment strategy known as the Dogs of the Dow, and applied it to UK stocks. How are the investments doing?
“We and consensus have been guilty of failing to reflect the impact of future revenue externalisation and asset disposals on revenue and earnings per share growth,” said analyst Jeffrey Holford.
Merck received a Complete Response Letter from the US Food and Drug Administration on the use of Sitagliptin
Archive
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
A study of more than 300,000 people spanning six countries showed Farxiga significantly cut the risk of death or heart failure in diabetes sufferers
Investments and investor services
The druggies and miners were on offer early on – although the movements were barely perceptible on a lacklustre Monday morning.
The transaction provides an opportunity to transform Circassia's product portfolio and commercial presence.
Main share price risers and fallers in London at 4pm: Metal Tiger, Ilika
ZS-9 is a treatment for hyperkalaemia – a condition where potassium levels in the blood are too high
Archive
As I venture into the world of equity trading, here’s the background to my story and where I’m at now
FTSE 100 shares closed lower on Tuesday after investors turned edgy over Brexit plans which hit banking and retail shares as well as took sterling to an 8-week low against the US dollar
The biopharma company said it has made progress on the development of several cancer treatments
“Our clear preference is for specialty-focus and growth in the context of a strong-catalyst driven thematic or deep value,” Barclays said in a brief note to clients.
The new once-daily medicine is to improve blood sugar level control in adults where single treatments of the drugs have proved inadequate.
Astrazeneca has offloaded the US and Canada commercial rights of Zoladex to focus on new oncology medicines.
We’ve had the final results from Holy Trinity of the UK pharma industry ... which is the one to back?
AstraZeneca said patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival.
Investments and investor services
Around 3.15pm, the UK blue chip index was up over 21 points at 7,299, not far from the day’s peak of 7,307, and well above the day’s low of 7,253.
The main risers and fallers around 2.45pm included Metal Tiger, CloudTag, Laura Ashley ...
Investments and investor services
FTSE 100 shares closed lower, dragged down by weaker US stocks and a flurry of ex-dividend stocks in London
Investments and investor services
Shire’s results Thursday will update on how 2016 ended as it provides commentary and numbers on the fourth quarter, which will be consolidated to provide full-year numbers too.
Archive
Shire will complete the fourth-quarter results announcements from the FTSE 100-listed pharma giants following numbers from Astra and Glaxo
Archive
BP could please on Thursday as its recent quarterly updates have proved a little disappointing. GlaxoSmithKline will unveil its numbers Wednesday.
The important number for the mainly income-hunting investor base was the dividend, which was bumped up to US$2.80 a share – providing a chunky yield in excess of 5%.
Investments and investor services
The BoE said the UK economy will grow substantially faster than its downgraded forecasts made in the wake of last June's shock Brexit vote.
Archive
Vodafone, Astrazeneca and Vedanta are among the blue-chips due to report on Thursday.
The normally reliable investment strategy based on the "Dogs of the Dow" system has had a bad couple of years; what if we tweaked it?
Archive
The normally reliable investment strategy based on the "Dogs of the Dow" system has had a bad couple of years; what if we tweaked it?
Archive
Big names reporting this week: SSE, TalkTalk, AstraZeneca, Compass, Vedanta
FTSE 100 stocks fell further below 7200 on Monday after sterling gained strength against the US dollar in the aftermath of President Donald Trump's inauguration speech
It made the decision about the Opdivo and Yervoy combination after assessing the data available
FTSE 100 shares swung on Friday but ended down 10 points and below 7200 as the 45th President of the United States was being sworn in
The ‘pivotal’ study will now look at overall survival rather than just progression-free survival
FTSE 100 shares did it again on Thursday – the 11th successive record high close – as turbulence in sterling finally gave in to a further steady decline and helped push stocks higher. All except retailers, that is
Here we take a look at the medium and small cap companies included among Fleet Street's top stock market tips for 2017.
Richard Hunter is keeping tabs on AstraZeneca, GSK and ITV as we head into 2017
Investments and investor services
FTSE 100 shares closed back above 7,000 on Friday for the first time since late October
AstraZeneca’s application to use its closely-watched new drug durvalumab to treat bladder cancer has been accepted by US regulator, the Food and Drug Administration
The conventional forecasting tool-box is broken says the Swiss broker
FTSE 100 stocks marched higher on Wednesday with miners the top gainers